Effects of Routine Infant Vaccination With the 7-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization with Streptococcus pneumoniae in Children and Parents in the Netherlands - Impact of PCV-7 on pneumococcal carriage in infants and parents

ederlands Vaccin Instituut0 个研究点目标入组 990 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•These criteria are derived from the related MINOES study, in order to increase comparability with historical unvaccinated controls
•- The children have to be of normal health (same health criteria apply as used in well-baby clinics when a child receives a vaccination, e.g. also children with small increases in temperature or cold are seen as children with normal health)
•-They have to be willing and able to participate in the trial according to procedure
•-Presence of a signed informed consent (the parents/legally representatives have
•given written informed consent after receiving oral and written information)
•-The children have received the Prevenar® vaccinations according to the 3+1 schedule of the Dutch NIP
•-Parents are included when the 24-month-old children fulfil inclusion criteria

•These criteria are derived from the related MINOES study with PCV-7 unvaccinated children
•Previous vaccinations with Prevenar® using a schedule that differs from the Dutch 3+1 schedule
•Previous vaccinations with other pneumoccocal vaccines
•Previous vaccinations of older brother(s) and/or sister(s) and/or parents with a pneumococcal conjugate vaccine (e.g. brother(s) and/or sister(s) that participated in the MINOES trial)
•Chromosomal abnormalities or craniofacial abnormalities (like Trisomy 21 or schisis), known or suspected immunodeficiency disease or other medical conditions that will severely affect immunological responses to vaccinations or nasopharyngeal carriage rates.
•-Coagulation disorder/medication;Parents are excluded
•when they have a bleeding disorder/ anticoagulant medication (because of the transnasal swab)

发起方

ederlands Vaccin Instituut